Author

S. Nance

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Abstract B005: Synergistic targeting of EP300/CBP and EYA co-activators collapses the rhabdomyosarcoma core regulatory circuit

Rhabdomyosarcoma (RMS) is a high-risk pediatric sarcoma that resembles developing skeletal muscle. Transcriptional dysregulation drives RMS pathogenesis in tumors carrying chimeric transcription factors (“fusion-positive (FP)”), and those without (“fusion-negative” (FN)). Here, we develop a novel approach against RMS...

Brian J. Abraham, Annika L. Gustafson, S. Nance et al. · Cancer Research · 0 citations

Sep 2026

Abstract A022: Cell state-directed integrated functional genomics reveals TAB1 as a central controller of the neuroblastoma chemoresistant mesenchymal cell state

Resistance to conventional chemotherapies is a major cause of cancer patient relapse and subsequent death. The fundamental biological properties of tumor cells are not only driven by acquired genetic mutations, but also by aberrant epigenetic regulation leading to corresponding changes in the expressed transcriptome....

G. McKay-Corkum, Noha A. M. Shendy, S. Nance et al. · Cancer Research · 0 citations

Sep 2026

Abstract B011: Oncogenic neomorphic ATRX-in-frame fusion mutations mechanistically enforce a new immunotherapeutic vulnerability through altered epigenomic regulation

Children with high-risk neuroblastomas (NB) marked by in-frame fusion mutations in the ATRX chromatin remodeler (“ATRX-IFF”) display highly chemoresistant disease. As a result, despite multi-modality therapies, these children have poor overall survival. At present, there are no molecularly-targeted agents for these t...

M. A. Mohammad Nezhady, S. Sati, D. E. Prado et al. · Cancer Research · 0 citations